HBK Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

HBK Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-68,600	Closed	-$2.4M	–	1008
2019 Q1	$2.4M	Buy	68,600 +43,100	+169%	+$1.6M	0.02%	464
2018 Q4	$847K	Buy	25,500 +8,457	+50%	+$364K	0.01%	740
2018 Q3	$858K	Sell	17,043 -9,903	-37%	-$489K	0.01%	776
2018 Q2	$1.61M	Sell	26,946 -28,770	-52%	-$1.49M	0.01%	529
2018 Q1	$2.55M	Buy	55,716 +16,816	+43%	+$702K	0.02%	403
2017 Q4	$1.55M	Buy	+38,900	New	+$1.54M	0.01%	519
2016 Q4	–	Sell	-10,635	Closed	-$263K	–	874
2016 Q3	$263K	Buy	+10,635	New	+$241K	﹤0.01%	744
2016 Q2	–	Sell	-33,300	Closed	-$508K	–	1080
2016 Q1	$508K	Sell	33,300 -21,100	-39%	-$275K	﹤0.01%	729
2015 Q4	$731K	Sell	54,400 -7,100	-12%	-$110K	0.01%	650
2015 Q3	$863K	Buy	+61,500	New	+$1.14M	0.01%	623

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

HBK Investments's SUPN Position: Q2 2019 in Review

HBK Investments sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 68,600 shares — an estimated $2.4M sold.

HBK Investments first reported a position in SUPN in Q3 2015 and held it in 10 quarters. The position peaked at $2.55M in Q1 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

HBK Investments reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 68,600 Supernus Pharmaceuticals shares in Q2 2019, an estimated $2.4M.
HBK Investments first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 10 quarters.
HBK Investments's Supernus Pharmaceuticals position peaked at $2.55M in Q1 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.